Renal cell carcinoma, VHL-associated
|Ali Raza Khaki, MD|
Palo Alto, CA
Note: these are regimens tested in populations with a diagnosis of Von Hippel Lindau (VHL) Disease-associated renal cell carcinoma, please see the main RCC page for other regimens.
All lines of therapy
|back to top|
|Study||Years of enrollment||Evidence|
|Awaiting publication (MK-6482-004)||2018-ongoing||Phase II (RT)|
Note: dosing information is from the FDA labeling.
- Belzutifan (Welireg) 120 mg PO once per day
- MK-6482-004: NCT03401788